Gordon Moody

1.7k total citations
24 papers, 836 citations indexed

About

Gordon Moody is a scholar working on Oncology, Immunology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Gordon Moody has authored 24 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Immunology and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Gordon Moody's work include CAR-T cell therapy research (6 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Growth Hormone and Insulin-like Growth Factors (5 papers). Gordon Moody is often cited by papers focused on CAR-T cell therapy research (6 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Growth Hormone and Insulin-like Growth Factors (5 papers). Gordon Moody collaborates with scholars based in United States, Germany and United Kingdom. Gordon Moody's co-authors include Pedro J. Beltran, Elaina Cajulis, Frank J. Calzone, Robert Radinsky, Brian Belmontes, Patricia L. Mitchell, Yong Suk Chung, Henrik S. Olsen, Bernardetta Nardelli and Cynthia Sung and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Gordon Moody

23 papers receiving 808 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gordon Moody United States	11	303	281	209	156	139	24	836
Wichai Chinratanalab United States	11	512 1.7×	314 1.1×	89 0.4×	279 1.8×	164 1.2×	48	1.0k
Ofer Margalit Israel	15	382 1.3×	330 1.2×	127 0.6×	32 0.2×	67 0.5×	52	824
Shona Nag India	13	720 2.4×	228 0.8×	228 1.1×	122 0.8×	82 0.6×	34	1.0k
Mark Cornfeld United States	11	497 1.6×	294 1.0×	151 0.7×	66 0.4×	157 1.1×	33	838
Asima Mukhopadhyay India	17	641 2.1×	520 1.9×	72 0.3×	28 0.2×	83 0.6×	59	1.3k
Jens Voortman Netherlands	19	358 1.2×	427 1.5×	157 0.8×	99 0.6×	110 0.8×	41	890
Brian S. Henick United States	14	511 1.7×	189 0.7×	308 1.5×	87 0.6×	306 2.2×	57	854
Marek Pudełko Poland	16	920 3.0×	255 0.9×	160 0.8×	50 0.3×	117 0.8×	42	1.3k
Betty Glinsmann‐Gibson United States	15	272 0.9×	422 1.5×	45 0.2×	56 0.4×	111 0.8×	23	853
Michel D. Wissing Canada	15	221 0.7×	321 1.1×	202 1.0×	90 0.6×	52 0.4×	52	774

Countries citing papers authored by Gordon Moody

Since Specialization

Citations

This map shows the geographic impact of Gordon Moody's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Moody with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Moody more than expected).

Fields of papers citing papers by Gordon Moody

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Moody. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Moody. The network helps show where Gordon Moody may publish in the future.

Co-authorship network of co-authors of Gordon Moody

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Moody. A scholar is included among the top collaborators of Gordon Moody based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Moody. Gordon Moody is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Breen, Shannon, Rosa A. Carrasco, Kelly McGlinchey, et al.. (2024). Abstract 1435: Utilization of CLDN18.2 syngeneic mouse models to study chimeric antigen receptor T cells in immunocompetent mice. Cancer Research. 84(6_Supplement). 1435–1435.

Malhotra, Deepali, Eleanor Clancy‐Thompson, Bilal Omar, et al.. (2022). 469 Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT. Regular and Young Investigator Award Abstracts. A489–A489. 5 indexed citations

Harder, Nathalie, Markus Schick, Karma Dacosta, et al.. (2022). 339 Quantitative assessment of CAR-T cell therapy targets using computational pathology. Regular and Young Investigator Award Abstracts. A357–A357. 1 indexed citations

Gilbreth, Ryan, Cui Chen, Erin Sult, et al.. (2020). 112 Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy. SHILAP Revista de lepidopterología. A69.2–A70. 1 indexed citations

Luheshi, Nadia, Susannah L. Hewitt, Fabien Garçon, et al.. (2019). Abstract 5017: MEDI1191, a novel IL-12 mRNA therapy for intratumoral injection to promote TH1 transformation of the patient tumor microenvironment. Cancer Research. 79(13_Supplement). 5017–5017. 7 indexed citations

Luheshi, Nadia, Susannah L. Hewitt, Fabien Garçon, et al.. (2019). Abstract 5017: MEDI1191, a novel IL-12 mRNA therapy for intratumoral injection to promote T_H1 transformation of the patient tumor microenvironment. Immunology. 5017–5017. 1 indexed citations

Ross, Sandra L., Marika Sherman, Patricia McElroy, et al.. (2017). Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing. PLoS ONE. 12(8). e0183390–e0183390. 80 indexed citations

Belmontes, Brian, et al.. (2017). Abstract 2027: Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models. Cancer Research. 77(13_Supplement). 2027–2027. 18 indexed citations

Moody, Gordon, Brian Belmontes, Wei Wang, et al.. (2016). Antibody‐mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo. International Journal of Cancer. 139(6). 1340–1349. 19 indexed citations

10.

Beltran, Pedro J., Frank J. Calzone, Petia Mitchell, et al.. (2014). Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. Clinical Cancer Research. 20(11). 2947–2958. 41 indexed citations

11.

Moody, Gordon, Pedro J. Beltran, Petia Mitchell, et al.. (2014). IGF1R blockade with ganitumab results in systemic effects on the GH–IGF axis in mice. Journal of Endocrinology. 221(1). 145–155. 19 indexed citations

12.

Ross, Sandra L., Lynn Tran, Aaron Winters, et al.. (2012). Molecular Mechanism of Hepcidin-Mediated Ferroportin Internalization Requires Ferroportin Lysines, Not Tyrosines or JAK-STAT. Cell Metabolism. 15(6). 905–917. 116 indexed citations

13.

Liu, Liqin, Gordon Moody, Jeanne Pistillo, et al.. (2011). Abstract 1975: Discovery of a potent and selective Jak2 inhibitor that suppresses GM-CSF-induced STAT5 phosphorylation and Erythropoietin-induced reticulocytosis in vivo. Cancer Research. 71(8_Supplement). 1975–1975. 1 indexed citations

14.

Beltran, Pedro J., Gordon Moody, Petia Mitchell, et al.. (2011). Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing’s and Osteogenic Sarcoma Models. Journal of Pharmacology and Experimental Therapeutics. 337(3). 644–654. 65 indexed citations

15.

Beltran, Pedro J., Patricia L. Mitchell, Gordon Moody, et al.. (2008). Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. Journal of Clinical Oncology. 26(15_suppl). 4617–4617. 197 indexed citations

16.

Moody, Gordon, Petia Mitchell, Elaina Cajulis, et al.. (2007). AMG 479, a fully human anti IGF-1 receptor monoclonal antibody, is efficacious against Ewing’s sarcoma and osteosarcoma xenografts. Molecular Cancer Therapeutics. 6. 6 indexed citations

17.

Sung, Cynthia, Bernardetta Nardelli, David W. LaFleur, et al.. (2003). An IFN- β -Albumin Fusion Protein That Displays Improved Pharmacokinetic and Pharmacodynamic Properties in Nonhuman Primates. Journal of Interferon & Cytokine Research. 23(1). 25–36. 55 indexed citations

18.

Osborn, Blaire L., Henrik S. Olsen, Bernardetta Nardelli, et al.. (2002). Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics. 303(2). 540–548. 169 indexed citations

19.

Moody, Gordon. (1995). The roots, significance, value and legislation of gambling. Journal of Gambling Studies. 11(1). 35–59. 6 indexed citations

20.

Moody, Gordon. (1989). Parents of young gamblers. Journal of Gambling Studies. 5(4). 313–320. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact